ArticleCancer communications (London, England)2024
Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity.
Abstract readLetter
In one paragraph
Article in Cancer communications (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- An immuno-chemotherapeutic bone scaffold for tumor eradication and bone regeneration in drug-resistant osteosarcoma.Bioactive materials · 2026Article
- Mass Spectrometry-Based Screening Reveals Inhibitors of Cholesterol 25-Hydroxylase.ACS chemical biology · 2026Article
- Deciphering the Therapeutic and Preventive Potential of Dietary Tannins in Osteosarcoma: A Multi-Omics Approach Targeting TGFA and Immune Microenvironment Remodeling.Food science & nutrition · 2026Article
- The miR-16-1-3p suppresses proliferation and invasiveness via the MDM2-p53 axis in TGF-β1 signaling in osteosarcoma.Molecular therapy. Oncology · 2026Article
- TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.Cancer science · 2026Article
- TMEM158-mediated TGF-β signaling pathway modulates the sensitivity of TP53-deficient osteosarcoma to USP14 inhibitors.Molecular and cellular biochemistry · 2026Article
- From Bench to Bedside: Advancements in Precision Oncology and Drug Discovery for Osteosarcoma.Cancers · 2026Review
- TGF-β in tumor development and progression: mechanisms and therapeutics.Molecular biomedicine · 2026Review
- Exosomes derived from ADSCs suppress the fibrosis process of derma in secondary lymphedema.Scientific reports · 2026Article
- Characterization of Tumor Microenvironment and Prognosis of Regulatory T cells-Related Subtypes.Current medicinal chemistry · 2026Article
- TGF-beta inhibitors in cancer therapy: a review of the TGF-beta signal transduction pathway and current developments.EXCLI journal · 2026Review
- Osteosarcoma as a communication-driven disease: redefining tumor-bone signaling networks as therapeutic targets.Frontiers in oncology · 2026Review
- The Role of Epithelial-Mesenchymal Transition in Osteosarcoma Progression: From Biology to Therapy.Diagnostics (Basel, Switzerland) · 2025Review
- Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence.Frontiers in oncology · 2025Review
- Review
- Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).International journal of oncology · 2024Review
- Targeting transforming growth factor beta signaling in metastatic osteosarcoma.Journal of bone oncology · 2023Review
- Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.International journal of molecular sciences · 2023Review
Corrections and comments
- Update of
Authors and funding
10 authors.
Sung Hee ChoiDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-8102-5538
Jay Thomas MyersDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Suzanne Louise TomchuckDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Melissa BonnerDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Saada EidDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Daniel Tyler KingsleyDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Kristen Ashley VanHeystDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Seong-Jin KimMedPacto Inc., Seoul, Republic of Korea.
Byung-Gyu KimDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Alex Yee-Chen HuangDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-5701-4521
Funding
TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MTRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2MRESEARCH ONCOLOGY TRAINING GRANTT32CA059366 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JACKSON, MARK W. · 1993 to 2025
$5.5MMechanisms of TGF-β-induced resistance to proteasome inhibitors in multiplemyelomaR03CA259901 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KIM, BYUNG-GYU · 2022 to 2023
$161kc-Myc regulation by TGF-beta signaling as a therapeutic target in OsteosarcomaR03CA273468 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHOI, SUNG HEE · 2024 to 2025
$161kTHE MECHANISM OF TRANSFORMING GENE ACTIVATIONF32CA007250 · NCI · DANA-FARBER CANCER INSTITUTE · PI DIAMOND, ALAN · 1985 to 1986
–Andrew McDonough B+ FoundationCenter for Pediatric Immunotherapy at RainbowChildren' 's Cancer Research FundCuring Kids CancerHyundai Hope-on-Wheels Scholar Hope GrantMIB AgentsNCI NIH HHS K12 CA076917NCI NIH HHS K12CA076917NCI NIH HHS P30 CA043703NCI NIH HHS P30CA043703NCI NIH HHS R03 CA259901NCI NIH HHS R03CA259901NCI NIH HHS R03 CA273468NCI NIH HHS R03CA273468NCI NIH HHS T32 CA059366NCI NIH HHS T32CA059366NCI NIH HHS T32GM007250NIGMS NIH HHS T32 GM007250Sam Day FoundationSarcoma Foundation of AmericaSt. Baldrick's Foundation
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cell ProliferationOsteosarcomaAdministration, OralAnimalsBone NeoplasmsCell Line, TumorHumansMiceReceptor, Transforming Growth Factor-beta Type IXenograft Model Antitumor AssaysReceptor, Transforming Growth Factor-beta Type I
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.